-
公开(公告)号：US20240279298A1
公开(公告)日：2024-08-22
申请号：US18570551
申请日：2022-06-17
发明人： Weibing LIU , Xuchao HUANG , Xiaoqian ZHANG , Fangzhou WU , Lei WANG , Liang QU
IPC分类号： C07K14/605 , A61K38/00 , A61K45/06 , A61P3/08
CPC分类号： C07K14/605 , A61K45/06 , A61P3/08 , A61K38/00
摘要： A glucagon analog and the medical use thereof. Specifically, the glucagon analog has a significantly improved in vitro activity, excellent physical/chemical stability, and high solubility, and can be used to treat metabolic diseases such as hypoglycemia, obesity, and diabetes.
-
2.发明公开公开(公告)号：US20230220111A1
公开(公告)日：2023-07-13
申请号：US18013524
申请日：2021-07-02
发明人： Lei WANG , Xugang HE , Jin ZHANG , Xiao LIU , Dongmei HU , Yanping DU , Ran WU , Chenxi SHEN , Yang YANG , Changyong YANG
CPC分类号： C07K16/36 , A61P7/02 , A61K2039/505
摘要： Provided are an anti-FXI/FXIa antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof, as well as a pharmaceutical composition comprising the anti-FXI/FXIa antibody or the antigen-binding fragment thereof, and a method for treating and preventing a disease, in particular a method for treating thrombosis or thromboembolism-related diseases or disorders.
-
公开(公告)号：US20230190879A1
公开(公告)日：2023-06-22
申请号：US17927304
申请日：2021-05-28
发明人： Fangzhou WU , Lei WANG , Xuchao HUANG , Ran WU , Renzhi LIU , Haiqing HUA
IPC分类号： A61K38/26 , C07K14/605 , A61P3/04 , A61P3/10
CPC分类号： A61K38/26 , C07K14/605 , A61P3/04 , A61P3/10
摘要： Provided is a dual-agonist compound for both Glucagon-like Peptide-1 (GLP-1) and Glucose-dependent Insulinotropic Polypeptide (GIP) receptors and application thereof. In particular, provided are a polypeptide analog derived from GLP-1 and a pharmaceutically acceptable salt thereof, which has an agonist effect on human GLP-1 receptor and human GIP receptor and can be used for the treatment of metabolic diseases such as obesity, type II diabetes, and non-alcoholic fatty liver.
-
公开(公告)号：US20230041996A1
公开(公告)日：2023-02-09
申请号：US17783233
申请日：2020-12-08
发明人： Fangzhou WU , Jin ZHANG , Fei GAO , Ran WU , Cheng LIAO , Lei WANG
摘要： Provided are a calcium-sensing receptor (CaSR) agonist compound and application thereof. Specifically, provided are a series of polypeptide CaSR agonist compounds and pharmaceutically acceptable salts thereof, which have agonist effects on human CaSRs to reduce plasma parathyroid hormone and serum calcium ion levels, and can be used for treatment of metabolic diseases such as primary hyperparathyroidism, secondary hyperparathyroidism, and tumor-induced hypercalcemia.
-
-
-
搜索结果
4 条记录 (耗时 0.016 秒)
